A study 6 conducted on non-diabetic adults with a BMI over 30 found that individuals in the semaglutide group achieved an average weight loss of nearly 15% of their body weight, equivalent to approximately 34 pounds
As of February 2025, injectable semaglutide is no longer on the FDAs drug shortages list, so compounding pharmacies must stop producing it by May 2025 at the latest
AOD-9604 AOD-9604 is a synthetic peptide derived from a fragment of human growth hormone (HGH)
Some individuals may experience mild side effects, such as nausea or gastrointestinal discomfort
However, the formation of glucose in this manner is not quantitatively significant
Ozempic does not contain stimulants and does not directly influence energy metabolism in the way that, for example, thyroid hormones do